{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:00:18Z","timestamp":1790092818188,"version":"4.0.1"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:p>This Perspective discusses the ethical, scientific, clinical, and manufacturing implications of excluding patients living with HIV from gene therapies for sickle cell disease.<\/jats:p>","DOI":"10.1001\/jama.2026.15933","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:30:39Z","timestamp":1787153439000},"page":"1005","source":"Crossref","is-referenced-by-count":0,"title":["HIV Status Exclusion in Sickle Cell Gene Therapy"],"prefix":"10.1001","volume":"336","author":[{"given":"Daniel","family":"Prior","sequence":"first","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmanan","family":"Krishnamurti","sequence":"additional","affiliation":[{"name":"Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"18","key":"jpp260031r1","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease.","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"jpp260031r2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease.","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"jpp260031r3","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12879-020-05366-z","article-title":"Association of HIV infection with clinical and laboratory characteristics of sickle cell disease.","volume":"20","author":"Belis\u00e1rio","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"6","key":"jpp260031r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016.","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"33","key":"jpp260031r5","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research HIV Working Group.","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"jpp260031r6","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2352-3018(24)00212-1","article-title":"Global, regional, and national burden of HIV\/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021.","volume":"11","author":"GBD 2021 HIV Collaborators","year":"2024","journal-title":"Lancet HIV"},{"issue":"8","key":"jpp260031r7","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021.","volume":"10","author":"GBD 2021 Sickle Cell Disease Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"jpp260031r8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/sextrans-2011-050459","article-title":"Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study.","volume":"88","author":"Nouraie","year":"2012","journal-title":"Sex Transm Infect"},{"issue":"1","key":"jpp260031r9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review.","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"jpp260031r10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/ID9.0000000000000176","article-title":"AIDS, crisis and power to transform (text extract): UNAIDS global AIDS update 2025 (executive summary).","volume":"5","author":"Joint United Nations Programme on HIV\/AIDS","year":"2025","journal-title":"Infect Dis Immun"},{"issue":"19","key":"jpp260031r11","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1001\/jama.2026.4178","article-title":"FDA draft guidance for the use of bayesian methods in clinical trials.","volume":"335","author":"Gelman","year":"2026","journal-title":"JAMA"},{"issue":"8","key":"jpp260031r12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803\/AMC 071 trial.","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood"},{"issue":"12","key":"jpp260031r14","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1086\/652866","article-title":"Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma.","volume":"50","author":"Simonelli","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"10","key":"jpp260031r15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"jpp260031r16","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","article-title":"Fidanacogene elaparvovec for hemophilia B\u2014a multiyear follow-up study.","volume":"392","author":"Rasko","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"jpp260031r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26613","article-title":"HIV-1 proviral DNA in purified peripheral blood CD34+ stem and progenitor cells in individuals with long-term HAART; paving the way to HIV gene therapy.","volume":"10","author":"Tassaneetrithep","year":"2024","journal-title":"Heliyon"},{"issue":"11","key":"jpp260031r18","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3324\/haematol.2013.089052","article-title":"Stem cell mobilization in HIV seropositive patients with lymphoma.","volume":"98","author":"Re","year":"2013","journal-title":"Haematologica"},{"issue":"22","key":"jpp260031r19","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count\u2013guided interruption of antiretroviral treatment.","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"jpp260031r20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/cid\/ciab541","article-title":"Time to viral rebound after interruption of modern antiretroviral therapies.","volume":"74","author":"Li","year":"2022","journal-title":"Clin Infect Dis"},{"key":"jpp260031r21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00059-7","article-title":"Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.","author":"Lee","year":"2026","journal-title":"Lancet HIV"},{"issue":"5","key":"jpp260031r22","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.ymthe.2025.03.016","article-title":"Current and future treatments for sickle cell disease: from hematopoietic stem cell transplantation to in vivo gene therapy.","volume":"33","author":"Ball","year":"2025","journal-title":"Mol Ther"},{"issue":"5","key":"jpp260031r23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2174\/0115665232332412241118063211","article-title":"Development of lentiviral packaging cells and scale up of production to meet the growing demand in cell and gene therapy.","volume":"25","author":"van Heuvel","year":"2025","journal-title":"Curr Gene Ther"},{"issue":"13","key":"jpp260031r24","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/bloodadvances.2020003680","article-title":"Wild-type HIV infection after treatment with lentiviral gene therapy for \u00df-thalassemia.","volume":"5","author":"Hongeng","year":"2021","journal-title":"Blood Adv"},{"key":"jpp260031r25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1065377","article-title":"Clinical genome editing to treat sickle cell disease\u2014a brief update.","volume":"9","author":"Zarghamian","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"jpp260031r13","volume-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2024"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2853060\/jama_prior_2026_pp_260031_1789422095.79072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:04:41Z","timestamp":1790089481000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2853060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.15933","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,22]]}}}